Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 546

1.

Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.

DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F.

Arch Intern Med. 2006 Jan 9;166(1):57-63. Erratum in: Arch Intern Med. 2006 May 8;166(9):954.

PMID:
16401811
3.

Etanercept or infliximab: the patient's considerations.

Sherrick RC.

Arch Intern Med. 2006 Jul 10;166(13):1418; author reply 1418. No abstract available.

PMID:
16832010
4.

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M.

Pharmacoeconomics. 2001;19(10):1051-64.

PMID:
11735673
5.

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.

Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, van der Linden S.

Ann Rheum Dis. 2006 Feb;65(2):201-8. Epub 2005 Jul 13.

6.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S.

Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.

PMID:
19446156
7.
8.
9.

Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France.

Fautrel B, Woronoff-Lemsi MC, Ethgen M, Fein E, Monnet P, Sibilia J, Wendling D.

Joint Bone Spine. 2005 Dec;72(6):550-6.

PMID:
15996504
10.

Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.

Ollendorf DA, Peterson AN, Doyle J, Huse DM.

Am J Manag Care. 2002 May;8(7 Suppl):S203-13.

11.

Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.

Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

Curr Med Res Opin. 2008 Aug;24(8):2229-40. doi: 10.1185/03007990802229548. Epub 2008 Jun 23.

PMID:
18577308
12.
13.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

14.

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.

Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ.

Rheumatology (Oxford). 2007 Nov;46(11):1729-35.

15.
16.

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

Carter CT, Changolkar AK, Scott McKenzie R.

J Med Econ. 2012;15(2):332-9. doi: 10.3111/13696998.2011.649325. Epub 2012 Jan 6.

PMID:
22168788
17.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

20.

Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, van Vollenhoven RF.

Ann Rheum Dis. 2004 Sep;63(9):1075-8. Epub 2004 Apr 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk